Diabetes News

A post-marketing study of Medtronic's MiniMed 530G insulin pump showed the device reduced hypoglycemia in patients without significantly increasing hyperglycemia. The study focused on the device's Threshold Suspend feature that, when enabled, suspends insulin delivery for up to two hours when the sensor glucose value reaches a preset threshold.

The FDA has expanded the approved use for Roches' Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy (DR) in patients with diabetic macular edema (DME). Lucentis is administered by a physician as an injection into the eye once a month. It is intended to be used along with appropriate interventions to control blood sugar, blood pressure and cholesterol.The FDA granted Lucentis for DR with DME breakthrough therapy designation

Blood pressure-lowering treatment among patients with type 2 diabetes is associated with a lower risk of cardiovascular disease (CVD) and heart disease events and improved mortality, according to a study in the Feb.10 issue of JAMA.

Type 1 diabetes is much more deadly for women than men, a study of more than 200,000 people with the condition has found. The University of Queensland's School of Public Health research has shown that women with type 1 diabetes have a 40 percent increased risk of death from any cause and that they have more than twice the risk of dying from heart disease compared to men with this type of diabetes.

The average adult with diabetes spends $2,790 more a year treating the disease than they did in 1987, according to a new study conducted by researchers at the Centers for Disease Control and Prevention. The study is published in the journal Diabetes Care.

The U.S. Food and Drug Administration has approved Glyxambi (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company, for adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments. 

A new Cornell University study has found that rats receiving a strain of lactobacillus engineered to secrete a Glucagon-like peptide had up to 30% lower high blood glucose. The study was published Jan. 27 in the journal Diabetes. The study was a proof of principle, and future work will test higher doses to see if a complete treatment can be achieved, said John March, professor of biological and environmental engineering at Cornell University and the paper’s senior author.

The U.S. Food and Drug Administration today allowed marketing of the first set of mobile medical apps that allow people with diabetes to automatically and securely share data from a continuous glucose monitor (CGM) with other people in real-time using an Apple mobile device such as an iPhone.

In new research published in Endocrinology, Thomas Burris, PhD, chair of pharmacological and physiological science at Saint Louis University, reports that his team has found a way to prevent type I diabetes in an animal model. Type I diabetes is a chronic autoimmune disease that occurs when the body’s immune system destroys insulin producing pancreatic beta cells, resulting in insulin deficiency and hyperglycemia. Current treatments for type I diabetes focus on controlling blood sugar with insulin therapy and must continue throughout a person’s life.

In older patients with multiple medical conditions, aggressively controlling blood sugar with insulin and sulfonylurea drugs could lead to overtreatment and hypoglycemia, according to new research by Yale School of Medicine researchers.